false
OasisLMS
Login
Catalog
Clinical Spotlight Series: Hypertriglyceridemia & ...
7. Panel Discussion With Audience Questions and An ...
7. Panel Discussion With Audience Questions and Answers
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Panelists discussed GLP‑1 use in severe hypertriglyceridemia, noting real‑world data suggesting no major pancreatitis increase and possibly fewer events; guidelines don’t list hypertriglyceridemia as a contraindication, though caution is advised in patients with prior pancreatitis. They debated triglycerides as a cardiovascular risk factor: TGs are viewed more as a biomarker of insulin resistance/remnant particles than a direct LDL‑like causal factor, and benefits in REDUCE‑IT may reflect pleiotropic effects. For patients on fenofibrate with TG ~200, speakers often stop it if used for CV prevention (no proven benefit on-label), prioritizing statins/LDL lowering; fibrates remain reasonable when TG >500 to prevent pancreatitis. Pill burden and combination therapies were raised; triple “polypills” aren’t common, but emerging agents (e.g., olezarsen) may add benefit, with potential synergy with fibrates.
Meta Tag
Concept
Triglyceride
Concept
Hypertriglyceridemia
Concept
Pancreatitis
Concept
Fibrate
Concept
Statin
Keywords
GLP-1
hypertriglyceridemia
pancreatitis
triglycerides
fenofibrate
Triglyceride
Hypertriglyceridemia
Pancreatitis
Fibrate
Statin
×
Please select your language
1
English